Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (AU2015335907) Method and system for microbiome-derived diagnostics and therapeutics

Office : Australia
Application Number: 2015335907 Application Date: 21.10.2015
Publication Number: 2015335907 Publication Date: 28.04.2016
Publication Kind : A1
Prior PCT appl.: Application Number:US2015056767 ; Publication Number: Click to see the data
IPC:
C12Q 1/68
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
Q
MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1
Measuring or testing processes involving enzymes or micro-organisms; Compositions therefor; Processes of preparing such compositions
68
involving nucleic acids
Applicants: Ubiome, Inc.
Inventors:
Agents: Clark Intellectual Property Pty Ltd
Priority Data: 62/066,369 21.10.2014 US
62/087,551 04.12.2014 US
62/092,999 17.12.2014 US
62/146,855 13.04.2015 US
62/147,212 14.04.2015 US
62/147,362 14.04.2015 US
62/147,376 14.04.2015 US
62/206,654 18.08.2015 US
Title: (EN) Method and system for microbiome-derived diagnostics and therapeutics
Abstract: front page image
(EN) A method for diagnosing and treating an immune microbial dysfunction in a subject, the method comprising: receiving an aggregate set of biological samples from a population of subjects; generating at least one of a microbiome composition dataset and a microbiome functional diversity dataset for the population of subjects; generating a characterization of the immune microbial dysfunction based upon features extracted from at least one of the microbiome composition dataset and the microbiome functional diversity dataset, wherein the characterization is diagnostic of at least one of Crohn's disease, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), ulcerative colitis, and celiac disease; based upon the characterization, generating a therapy model configured to correct the immune microbial dysfunction; and at an output device associated with the subject, promoting a therapy to the subject based upon the characterization and the therapy model.